ABSTRACT Peak plasma concentrations of lignocaine were recorded in 41 patients receiving topically applied lignocaine for fibreoptic bronchoscopy. Adequate anaesthesia was achieved in all patients with an average dose per unit weight of 9 3 + 0 5 mg/kg (SEM) giving a mean peak plasma concentration of 2-9 + 0.5 mg/1-1 (SEM) (± SE 0.5). The plasma concentration exceeded toxic levels of 5.0 mg/l-1 in only two patients, and no complications were observed. Peak concentrations were influenced only by dose per unit weight administered and not by factors considered likely to influence mucosal absorption from the bronchial tree, such as sputum production, airflow obstruction, or cigarette smoking. A major proportion of the total dose of lignocaine was requited to anaesthetise the nose, pharynx, and larynx, only a small proportion being needed for the bronchial tree. Lignocaine gel (20% w/v) was preferred by patients, and in a study of 10 volunteers, produced lower plasma concentrations when used as a topical anaesthetic than did lignocaine aerosol (100% w/v) or lignocaine solution (4 % w/v).
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Fibreoptic bronchoscopy is safe and simple, but topical anaesthesia of the upper respiratory tract is necessary for adequate examination. Lignocaine is commonly used but is well absorbed from mucosal surfaces, producing significant plasma concentrations' and may therefore not be ideal.2 Lignocaine toxicity is related to plasma concentrations3 and levels in excess of 5 mg/l-1 may result in convulsions4 or heart block.5 6 Little is known of the comparative mucosal absorption of the common preparations of lignocaine: 2% w/v gel; 4% w/v solution (also 1 % w/v), and 10% w/v aerosol. Lignocaine solution when applied to the respiratory tract is absorbed from mucosa of the tracheobronchial tree or even alveoli. 7 However, there is little information on the effects of lung disease or smoking on lignocaine absorption from the airways.
We have studied 41 patients undergoing fibreoptic bronchoscopy, to determine the safe limits for topical administration of lignocaine, and to determine whether higher total doses were needed in patients with lung disease. Separately, absorption through buccal and nasal mucosa has been studied in volunteers.
Methods

PATIENTS STUDY
Forty-one patients undergoing fibreoptic bronchoscopy were studied, each having given informed consent. On the morning of study each patient was asked to produce as much sputum 10 volunteers, who had given informed consent, were studied. Five on separate days in random order, either gargled and drank lignocaine solution (4% w/v), or had lignocaine aerosol (10% w/v), applied to their oropharynx. Excess amounts were swallowed as is the usual case during endoscopy. A similar dose per unit body weight was used with each preparation (6-8 mg/kg). Venous blood was again taken at 10 minute intervals initially for the first hour, then at 20 minute intervals for the second hour to determine plasma lignocaine concentrations. Because of the unpleasant nature of the aerosol, a lower dose per unit body weight (2-2 mg/kg) was applied to the anterior nares in five volunteers and was contrasted with effect of the same dose per unit body weight of lignocaine gel (2% w/v). On separate days, the two lignocaine preparations were studied in random order and peak plasma lignocaine concentrations and time to peak were determined. Comparisons of the two preparations were made using paired t tests."
Results
PATIENT STUDY
The results are recorded in the figure. A mean total dose of 623 ± 41-1 mg (SEM) lignocaine was administered to our 41 patients. The average dose per unit body weight was 9-3 ± 0-5 mg/kg (SEM) which gave an average peak plasma concentration of 2-9 ± 0 5 mg/l-' (SEM). Although two patients had peak concentrations in excess of a recognised In nine patients receiving gel, an average 25 ± 4 5% (SE) was administered to the nose as gel and they received a greater proportion of the total dose as 1 % w/v lignocaine down the bronchoscope to the bronchial tree, 38 4% (± SE 4-2%). Patients receiving both regimens had similar dose ranges of lignocaine (see figure) .
VOLUNTEER STUDY
The results are recorded in the table. A comparison of absorption from the oropharynx of lignocaine aerosol and solution showed that the 4 % w/v solution gave significantly higher peak plasma concentrations than the aerosol, 2 4 mg/l compared with 1 9 mg/l (p < 0 05). This average concentration was achieved more quickly in solution (24 minutes) than for aerosol (50 minutes) (p < 0-05).
When one-third of this dose was applied to the nose, lignocaine aerosol was absorbed better than gel, giving peak plasma concentrations of 0-8 mg/l compared with 0-52 mg/l for gel (p < 0 05). Time to peak for aerosol was 46 minutes compared with only 34 minutes for the gel (p < 0-05).
Discussion
Adequate anaesthesia was achieved in all 41 patients enabling full bronchoscopic examination. The low risk associated with topical lignocaine anaesthesia to the upper airways was confirmed12. In 32 patients this was provided on average by 14 sprays of 100% w/v lignocaine aerosol to the nose and throat, 8 ml of 4% w/v lignocaine solution to the pharynx and vocal cords, and 14 ml of 1 % w/v solution for the bronchial tree. Even with our wide range in total dosage, larger than reported in earlier studies,8 most patients had peak plasma concentrations of lignocaine well below a toxic level. Use of an alternative regimen, in which lignocaine gel was applied to the nose (an average of 8 ml, 4 ml to each nostril), followed by lignocaine solution 4% w/v above the vocal cords and 1 % w/v below the cords, proved to be more acceptable to patients. It gave slightly (but not significantly) lower peak plasma concentrations but was not considered less anaesthetically powerful and caused less epiphora than lignocaine aerosol.
Only two patients had peak plasma concentrations in excess of 5 mg/l. One with a high concentration (9-6 mg/l) (although revealing no clinical evidence of renal or hepatic dysfunction at the time of bronchoscopy) was found on postmortem examination four weeks later to have extensive liver metastases from his bronchial carcinoma. It is possible that the high peak concentration represented occult metabolic hepatic dysfunction. Renal and hepatic function are important in the clearance of lignocaine, and previous reports of high peak plasma concentrations after topical lignocaine have been confined to patients with dysfunction. '3 In this study we did not show airflow obstruction, sputum production, or cigarette smoking habit to have any influence on peak plasma lignocaine concentrations. This contrasts with previous observations where tracheobronchial absorption of Peak plasma concentrations of lignocaine are functions of rate of mucosal absorption, distribution in tissues, and rate of elimination of the drug from the body. The differences in peak plasma concentrations in studies of volunteers are likely to reflect variations in rate of mucosal absorption.3 Absorption was more rapid and complete with the 4% w/v solution of lignocaine than from the other two preparations. Lignocaine was least well absorbed in gel form. When deciding on the most suitable topical anaesthesia, consideration should be given to absorption, as an ideal topical agent should achieve local anaesthesia with little absorption, producing low plasma concentrations. On these grounds the gel preparation of 2% (w/v) lignocaine would appear most suitable. It provides adequate topical anaesthesia particularly for nasal passages, causing little pain and epiphora, as well as acting as a lubricant. As excess gel is swallowed, none is likely to enter the trachea, unlike the aerosol.
In conclusion, topical anaesthesia with lignocaine during fibreoptic bronchoscopy has again proved safe. Only two out of 41 patients developed peak plasma concentrations associated with toxicity, and all patients remained free of toxic symptoms. Most of the topical anaesthetic was required for the nose, pharynx, and larynx. Application of lignocaine gel 2% w/v to the nose followed by solution to the larynx appeared a more satisfactory regimen than applying lignocaine aerosol 10% w/v to the nose.
